SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : TGEN - Targeted Genetics Corporation
TGEN 9.890+3.1%Oct 31 3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Mike McFarland who wrote (536)5/19/2008 7:35:42 PM
From: Mike McFarlandRead Replies (2) of 557
 
I listened with IE/WMP, and no slides loaded, but I'm
pretty sure there are no slides available with these
R&R archives. HSP went over rnai-aav, espressed rnai and
the blindness study, she touched on the rationale for
the AAV-TNFR studies and endpoints for the trial, she
mentioned the proof of concept Huntingtons and the PNAS
paper and getting around toxicity with microrna (but
did say toxicity several times and I didn't get the
impression that this is quite ready for much in the
way of human testing) and she mentioned the heart failure
program. I didn't hear anything that sounded like new
information.

She said there would be data at the EULAR meeting. I did
not hear anything about the ASGT meeting.

And she said nothing about the vaccine work.

TGEN had $13M at the end of the quarter, and that is
their burn rate.

Ren Benjamin at Rodman & Renshaw has coverage now
(starting May 1st apparently)
biz.yahoo.com

Partnerships and licensing hopefully will generate
some funds, otherwise I should think TGEN will have
to be bought out, or of course do yet another round
of dilution--which would be a shame since there are
only 20M shares outstanding now, so you could get the
shares up with some good newsflow. My guess is that
the market expects dilution, and that is why the
shares stay below a buck. And one year of burn looks
ugly too. With over $300 million of accumulated losses
and a marketcap of just $15M, there might be some sort
of tax accounting angle if this is acquired.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext